Skip to main content
Contact Us
Subscribe
E-Edition
35°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.1120
-0.0034 (-2.95%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment
November 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
November 25, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting
November 18, 2024
Via
Investor Brand Network
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
November 18, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 15, 2024
Via
ACCESSWIRE
New Graphene Chip Could Revolutionize Brain Cancer Treatment
November 08, 2024
Via
Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
November 04, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
October 10, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position
November 15, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event
November 04, 2024
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance
November 01, 2024
Via
Investor Brand Network
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
November 01, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
October 08, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
September 23, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
August 27, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
August 22, 2024
Via
ACCESSWIRE
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
October 25, 2024
Via
AB Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering
October 24, 2024
Via
Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
October 23, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment
October 10, 2024
Via
Investor Brand Network
Jimmy Carter Survival Thanks to Novel Cancer Immunotherapy Treatment
October 04, 2024
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum
September 23, 2024
Via
Investor Brand Network
WHO Review Says No Link Between Mobile Phones, Brain-Cancer Development
September 13, 2024
Via
Investor Brand Network
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
September 12, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
Via
Investor Brand Network
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode
September 03, 2024
Via
Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
August 27, 2024
Via
Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment
August 22, 2024
Via
Investor Brand Network
Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer
August 21, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.